Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LBPH NASDAQ:LFCR NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$27.35▼$60.03$2.34B11.37 million shsN/ALFCRLifecore Biomedical$7.42-4.1%$7.52$3.68▼$8.85$289.54M0.65125,028 shs120,479 shsMNOVMediciNova$1.30+2.4%$1.31$1.13▼$2.55$62.29M0.3550,710 shs7,125 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+71.96%LFCRLifecore Biomedical+1.44%+0.13%-5.26%+15.35%+28.15%MNOVMediciNova-2.31%-6.62%-0.78%-8.63%+12.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALFCRLifecore Biomedical0.7224 of 5 stars1.30.00.00.01.74.20.6MNOVMediciNova2.456 of 5 stars3.83.00.00.02.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals 2.17Hold$65.679.48% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.007.82% UpsideMNOVMediciNova 3.50Strong Buy$7.00438.46% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, LFCR, and LBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.005/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/ALFCRLifecore Biomedical$128.87M2.15N/AN/A$0.37 per share20.05MNOVMediciNovaN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.23N/AN/AN/AN/A-33.03%-30.90%N/ALFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/14/2025 (Estimated)Latest MNOV, LFCR, and LBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025Q4 2025LFCRLifecore Biomedical-$0.09N/AN/AN/A$35.36 millionN/A8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/AN/A8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A15.9715.97LFCRLifecore Biomedical113.762.841.59MNOVMediciNovaN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%LFCRLifecore Biomedical83.36%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%LFCRLifecore Biomedical32.20%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals2039.05 million37.23 millionOptionableLFCRLifecore Biomedical69037.41 million25.36 millionOptionableMNOVMediciNova1049.05 millionN/AOptionableMNOV, LFCR, and LBPH HeadlinesRecent News About These CompaniesMediciNova: Q2 Earnings Snapshot1 hour ago | sfgate.comMediciNova (MNOV) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comMediciNova signs standby equity purchase agreement for up to $30MAugust 1, 2025 | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1, 2025 | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31, 2025 | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31, 2025 | globenewswire.comMediciNova's (MNOV) Buy Rating Reiterated at D. Boral CapitalJuly 25, 2025 | marketbeat.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | globenewswire.comMediciNova, Inc. (MNOV) stock price, news, quote & history – Yahoo ...July 12, 2025 | au.finance.yahoo.comMediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comMediciNova price target lowered to $5 from $6 at B. RileyJune 17, 2025 | finance.yahoo.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14, 2025 | globenewswire.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MNDDecember 5, 2024 | quiverquant.comQMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, LFCR, and LBPH Company DescriptionsLongboard Pharmaceuticals NASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Lifecore Biomedical NASDAQ:LFCR$7.42 -0.32 (-4.13%) Closing price 04:00 PM EasternExtended Trading$7.42 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.MediciNova NASDAQ:MNOV$1.30 +0.03 (+2.36%) Closing price 04:00 PM EasternExtended Trading$1.29 -0.01 (-0.77%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access